http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110407812-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 |
| filingDate | 2019-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110407812-B |
| titleOfInvention | Indazole piperidine pyrimidine derivative and preparation method and application thereof |
| abstract | The invention belongs to the technical field of medicines, and particularly relates to an indazole piperidine pyrimidine derivative, and a preparation method and application thereof. The indazole piperidine pyrimidine derivative provided by the invention replaces an acrylamide structure forming a covalent bond on the basis of keeping a third-generation EGFR inhibitor pyrimidine parent ring, so that a non-covalent bond combined inhibitor is obtained. The results of the drug activity tests show that the compounds show excellent in-vitro inhibition effect on human lung cancer H1975 cells. Meanwhile, most compounds have less toxicity to normal human cells than lung cancer cells, show better selectivity and can be used for further developing anti-cancer drugs. |
| priorityDate | 2019-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 93.